## Clinical Context This patient has chronic aortic regurgitation (AR) secondary to rheumatic heart disease presenting with **symptoms** (palpitations and dyspnea), an **aortic root diameter of 50 mm**, and a **borderline-reduced LVEF of 50%**. The combination of these findings meets guideline-based indications for aortic valve replacement (AVR). ## Classification of Aortic Regurgitation Severity | Parameter | Mild | Moderate | Severe | | --- | --- | --- | --- | | Jet width (% LVOT) | <25% | 25–65% | >65% | | Regurgitant volume (mL/beat) | <30 | 30–59 | ≥60 | | Aortic root diameter | <40 mm | 40–50 mm | ≥50 mm | | LVEF | Normal | Normal–mildly ↓ | ↓ | **Key Point:** An aortic root diameter of **≥50 mm** is classified as severe dilatation per ACC/AHA 2021 and ESC 2021 guidelines, and in a **symptomatic** patient with **LVEF at 50%** (borderline impaired in the context of chronic volume overload), this constitutes a clear surgical indication. ## Indications for Aortic Valve Replacement in AR (ACC/AHA 2021 / ESC 2021) **High-Yield:** Surgery is indicated when ANY of the following are present: 1. **Symptomatic severe AR** (dyspnea, angina, syncope) — Class I 2. **Asymptomatic severe AR with LVEF ≤55%** (ACC/AHA) or **LVEF <50%** (ESC) — Class I 3. **Aortic root/ascending aorta ≥50 mm** in patients with bicuspid valve or connective tissue disease, or **≥55 mm** in others — Class I 4. **Severe AR undergoing other cardiac surgery** — Class I This patient is **symptomatic** (dyspnea, palpitations) AND has **LVEF of 50%** (below the ACC/AHA threshold of 55% and at the ESC threshold of <50%), AND has an **aortic root of 50 mm** — meeting multiple Class I indications simultaneously. ## Why Immediate AVR is Correct 1. **Symptomatic status**: Dyspnea and palpitations in the setting of AR indicate hemodynamic compromise — medical therapy alone is insufficient. 2. **LVEF 50%**: In chronic AR, the LV compensates with eccentric hypertrophy; an LVEF of 50% represents significant myocardial impairment (normal compensation should maintain LVEF >60%). This is a Class I indication for surgery per ACC/AHA 2021 (LVEF ≤55%). 3. **Aortic root 50 mm**: At or above the threshold for surgical intervention, particularly in a symptomatic patient. 4. **Delaying surgery risks irreversible LV dysfunction**: Once LVEF falls further, post-operative LV recovery is compromised. ## Why Other Options Are Incorrect - **Option A (Amlodipine + Lisinopril, echo in 6 months):** Vasodilators are appropriate for **asymptomatic** patients with preserved LV function who do not yet meet surgical criteria. This patient is symptomatic with borderline LVEF — delaying surgery with medical therapy risks irreversible LV damage. - **Option C (Cardiac catheterization):** Echocardiography is sufficient to assess AR severity; catheterization is not routinely required before AVR unless coronary artery disease is suspected (not indicated here as first step). - **Option D (Beta-blocker monotherapy):** Beta-blockers are **contraindicated** in chronic AR — they prolong diastole, increase diastolic runoff time, and worsen regurgitant volume. This is a dangerous choice. ## Management Algorithm for Chronic AR **Clinical Pearl:** In chronic AR, LVEF is a critical decision point. Because the LV dilates to compensate, an LVEF of 50% in AR is equivalent to significant systolic dysfunction — do not be falsely reassured by a "preserved" LVEF that is actually below the expected compensatory range. **Reference:** ACC/AHA 2021 Valvular Heart Disease Guidelines (Otto CM et al., JACC 2021); ESC/EACTS 2021 Guidelines on Valvular Heart Disease (Vahanian A et al., Eur Heart J 2022).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.